Physician profile
David Perry Johnson
NPI 1902871155
$5,184.49
in general payments reported to CMS, 2019-2025
33 companies · $376 in 2025
The $376 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $711 · 2021: $1,262 · 2022: $762 · 2023: $628 · 2024: $719 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $986.24 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $485.47 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $484.88 | 2020-2023 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $387.83 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $386.55 | 2019-2024 | |
| Pfizer INC. | $254.71 | 2019-2024 | |
| Edwards Lifesciences Corporation | $237.57 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $196.34 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $189.67 | 2019-2024 | Camzyos |
| Amarin Pharma, INC. | $167.14 | 2020-2022 | |
| Boston Scientific Corporation | $135.12 | 2022-2025 | Watchman Access System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Akcea Therapeutics, INC. | $125.00 | 2020 | |
| Cvrx, INC. | $114.75 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $114.71 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $109.97 | 2024-2025 | Opsumit, Uptravi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $89.71 | 2019-2025 | |
| Abbott Laboratories | $89.61 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.15 | 2019-2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $76.38 | 2023-2025 | Amvuttra, Onpattro |
| Abiomed | $73.51 | 2024-2025 | Impella |
| Kestra Medical Technology Services, INC. | $69.62 | 2022 | |
| Vital Connect, INC | $39.34 | 2024 | Vitalpatch Rtm |
| Regeneron Healthcare Solutions, INC. | $39.20 | 2019 | |
| Astellas Pharma US INC | $36.16 | 2021-2022 | |
| Biotronik INC. | $30.29 | 2025 | Orsiro Mission |
| Lombart Brothers, INC. | $29.58 | 2019 | |
| Heartflow, INC. | $29.45 | 2025 | |
| Lantheus Medical Imaging, INC. | $29.22 | 2023 | Definity |
| Novo Nordisk INC | $23.86 | 2021 | |
| Sobi, INC | $20.50 | 2025 | |
| Tactile Systems Technology INC | $17.73 | 2025 | Nimbl, Flexitouch Plus |
| Chiesi USA, INC. | $17.52 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.